NCT00495677 is a Phase 2 clinical trial of PF-00232798 in HIV, sponsored by Pfizer.

Who is sponsoring NCT00495677?

NCT00495677 is sponsored by Pfizer.

What drugs are being tested in NCT00495677?

Interventions in NCT00495677: PF-00232798, PF-00232798, PF-00232798, PF-00232798, PF-00232798, PF-00232798.

Is NCT00495677 still recruiting?

NCT00495677 is currently completed. Last updated 26 August 2013.

Are results published for NCT00495677?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2013-08-26 · How we verify

NCT00495677

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomised, Double-Blind, Placebo-Controlled, Multicentre Study In Asymptomatic Hiv-Infected Patients To Investigate The Pharmacodynamics, Pharmacokinetics, Safety And Toleration Of PF-00232798

Completed Phase 2 Results posted Last updated 26 August 2013

What this trial tests

Phase 2 trial testing PF-00232798 in HIV in 43 participants. Completed in 1 September 2008.

Timeline

1 June 2007

Primary endpoint
1 September 2008

1 September 2008

Quick facts

Lead sponsor	Pfizer
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	43
Start date	1 June 2007
Primary completion	1 September 2008
Estimated completion	1 September 2008
Sites	2 locations across Germany

Drugs / interventions tested

PF-00232798 — full drug profile →
PF-00232798 — full drug profile →
PF-00232798 — full drug profile →
PF-00232798 — full drug profile →
PF-00232798 — full drug profile →
PF-00232798 — full drug profile →

Conditions studied

HIV — all drugs for HIV →

Sponsor

Pfizer — full company profile →

Who can join

Adults 18 to 55, male only, with HIV. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change From Baseline in Log 10-transformed Human Immunodeficiency Virus (HIV) Viral Load at Day 11
Time frame: Baseline, Day 11
Viral load was determined using the Roche COBAS Taqman HIV-1 assay with a lower limit of detection of 40 copies per milliliter (copies/mL). Samples with an initial reading of less than 1,000,000 copies/mL were diluted into range and re-assayed.

Sponsor's own description

To assess the viral load response, safety, tolerability and pharmacokinetics of multiple oral doses of PF 00232798 in HIV-positive patient volunteers.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

HIV-1 Entry and Prospects for Protecting against Infection.
Bruxelle JF, Trattnig N, Mureithi MW, Landais E, et al · · 2021 · cited 10× · PMID 33499233 · DOI 10.3390/microorganisms9020228

Verify or expand the search:

Other recruiting trials for HIV

Currently open trials in the same condition.

NCT06705478 — Pramipexole Versus Escitalopram to Treat Major Depressive Disorder (MDD) and Comorbid MDD With Mild Neurocognitive Disor · Phase 2 · recruiting
NCT07221214 — GLP-1 Receptor Agonists to Decrease Ethanol and CVD Risk in HIV · Phase 2 · recruiting
NCT07226128 — The Effects of Cognitive Behavioral Therapy on Insulin Resistance in People With HIV · NA · recruiting
NCT07390474 — Clinical Trial to Evaluate the Safety and Immunogenicity of the V2 Apex-Directed Immunogens DV201P-RNA and DV202B1-RNA i · Phase 1 · recruiting
NCT07390955 — A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1 · Phase 1 · recruiting

Other Pfizer trials

Trials by the same sponsor.

NCT04982848 — Korea Post Marketing Surveillance (PMS) Study of Talzenna® · not yet recruiting
NCT06873191 — A Study to Learn More About Tukysa Once it is Out in the Korean Market · not yet recruiting
NCT07497854 — A Study to Learn About the Study Medicine NURTEC® ODT 75 mg After it is Released Into the Markets in Korea · not yet recruiting
NCT06507904 — A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Anta · Phase 1 · not yet recruiting
NCT06864585 — A Study to Learn About the Study Medicine - Zavicefta in Patients With Sepsis or Loss of Kidney Function in Japan · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00495677 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pfizer
Last refreshed: 26 August 2013

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00495677.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing